



February 1, 2018

## **Prothena to Report Fourth Quarter and Full Year 2017 Financial Results and Host Webcast Conference Call on February 14**

DUBLIN, Ireland, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapies, announced today that it will report its fourth quarter and full year 2017 financial results on Wednesday, February 14<sup>th</sup>, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET.

The conference call will be made available on the Company's website at [www.prothena.com](http://www.prothena.com) under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days.

To access the call via dial-in, please dial (877) 887-5215 (U.S. toll free) or (315) 625-3069 (international) five minutes prior to the start time and refer to conference ID number 2186715. A replay of the call will be available until February 28, 2018 via dial-in at (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 2186715.

### **About Prothena**

Prothena Corporation plc is a global, late-stage clinical biotechnology company establishing fully integrated research, development and commercial capabilities and focused on advancing new therapies in the neuroscience and orphan categories. Fueled by its deep scientific understanding built over decades of research in protein misfolding, Prothena seeks to fundamentally change the course of grave or currently untreatable diseases associated with this biology. Prothena's pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002/RG7935) and ATTR amyloidosis (PRX004). The Company continues to advance additional discovery programs against targets including tau, A $\beta$  (Amyloid beta) and ALECT2 where its deep scientific understanding of disease pathology can be leveraged. For more information, please visit the Company's website at [www.prothena.com](http://www.prothena.com).

### **Media & Investor Contact:**

Ellen Rose, Head of Communications  
650-922-2405, [ellen.rose@prothena.com](mailto:ellen.rose@prothena.com)